Latest review shows intensive care mortality from COVID-19 continued to fall in 2020, but improvement is slowing

February 01, 2021

A meta-analysis of global studies published in Anaesthesia (a journal of the Association of Anaesthetists) shows that intensive care morality from COVID-19 has continued to fall since the start of the pandemic, but the improvement is slowing and may have plateaued. The study is by Professor Tim Cook (Consultant in Anaesthesia and Intensive Care Medicine, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK, and Honorary Professor, School of Medicine, University of Bristol, UK) and colleagues.

A previous meta-analysis* by Cook and colleagues, published in July, 2020, concluded that overall mortality of COVID-19 patients in intensive care units (ICUs) has fallen from almost 60% at the end of March 2020 to 42% at the end of May 2020 -- a relative decrease of around one third. This new study shows that, in studies up to October, 2020, ICU mortality has fallen again to 36%. Thus, while the situation is still improving, the pace of progress has slowed substantially.

In this study, the authors used data from 52 observational studies including 43,128 patients, and, in addition to studies from Europe, North America and China that had been included in the earlier review, this study included first reports from the Middle East, South Asia and Australia, as well as four new national or regional registries.

The authors explain that, in the last few months, several studies have clarified which treatments do and do not provide benefit in the ICU management of COVID-19. Steroids (particularly dexamethasone) were shown in early June to improve survival in patients who are oxygen-dependent or receiving mechanical respiratory support, while other drugs including hydroxychloroquine, azithromycin, lopinavir/ritonavir and remdesivir have been shown to have no clear mortality benefit. They also note that management of COVID-19 has also likely evolved over the year with changes in approaches to oxygen therapy, fluid therapy and management of blood clotting.

The data show that in most geographical regions the ICU mortality rate from COVID-19 is 30- 40%. Two geographical regions fall outside these limits and are statistically significantly different from other geographical regions. A single registry report from Victoria State in Australia (home to the city of Melbourne) reports very low mortality of 11%. Conversely in the Middle East, mortality from a study including four countries is high at 62%. There are several potential explanations for this finding, including the fact that studies from the Middle East included patients early in the pandemic when mortality was higher, while the patients included in Australia were later in the pandemic when mortality was lower.

The authors comment that the analysis is limited by the fact that there is no global standardisation of what constitutes intensive care, entry criteria for patients, admitted patients' underlying health characteristics and severity of critical illness, or reporting on the nature or intensity of treatments. Thus direct comparisons between studies from different regions can be difficult.

The authors say: "Our analysis includes studies published only up to October 2020. Since then, several variant viruses have emerged and in some countries transformed the trajectory of the pandemic through December 2020 and into January 2021. This has increased the demand on ICU in those locations and will merit further analysis in due course. To counter this, vaccination is now available in many countries and we can hope that this will also, over several months, positively impact on the pandemic trajectory and demand on ICU care."

They conclude: "After our first meta-analysis last year showed a large drop in ICU mortality from COVID-19 from March to May 2020, this updated analysis shows that any fall in mortality rate between June and October 2020 appears to have flattened or plateaued."
-end-


AAGBI

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.